Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Over the past month, shares of this HIV and hepatitis C drugmaker have returned +1.9%, compared to the Zacks S&P 500 composite's -3.3% change. During this period, the Zacks Medical - Biomedical and ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc (SHEL) and Gilead Sciences, Inc. (GILD).

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

Situated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...